SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumors cells and have fewer side effects. SBRT may work just as well as hypofractionated radiation therapy at treating patients with biochemically recurrent or oligometastatic prostate cancer, but with a shorter treatment time and possibly fewer side effects.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak gruczołowy prostaty
- •Wiek co najmniej 18 lat
- •PSA (marker nowotworu) między 0,1 a 2,0 ng/mL, zmierzony do 90 dni przed zapisaniem się
- •Rak prostaty rozprzestrzeniony maksymalnie na 5 miejsc w ciele
- •Zdrowy stan ogólny (ocena ECOG 0-2)
- •Może rozpocząć leczenie w ciągu 120 dni od zapisania się do badania
- •Podpisał świadomą zgodę na uczestnictwo
✗ Disqualifies
- •Poprzednia radioterapia w okolicy miednicy
- •Wcześniejsze leczenie hormonalne raka prostaty z PSA ≥0,1 ng/mL
- •Aktywne zapalenie jelita grubego lub Crohna w odbytnici
- •Wcześniejsza chemioterapia z powodu raka prostaty
- •Zawał serca lub poważna niewydolność serca w ostatnich 6 miesiącach
- •Obecność na liście oczekujących na przeszczep
- •Rak rozprzestrzeniający się na więcej niż 5 miejsc w ciele
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (6)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic Health System in Albert Lea
Albert Lea, United States
Mayo Clinic Health System - Mankato
Mankato, United States
Mayo Clinic in Rochester
Rochester, United States
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, United States
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.